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We have generated in-frame fusions between the mouse dihydrofolate reductase (DHFR) and parts of the a-factor MFAI gene to explore the 
potential of a-factor as a secretion signal for larger polypeptides. We demonstrated that the fusion proteins are famesylated by comparing the 
mobility of fusion proteins prepared from a wild-type strain and a farnesyltransferase mutant (stel6/raml) on SDS-gels and by an in vitro 
famesylation assay. In contrast o unmodified DHFR, the fusion proteins could be sedimented from cell extracts by centrifugation. Solubilization 
experiments indicated that the highly hydrophobic a-factor moiety renders the fusion proteins insoluble, explaining why the fusions are not secreted 
into the culture medium. 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
Unlike its counterpart &-factor, which is secreted in 
a classical signal sequence-dependent manner [I], the 
yeast mating pheromone, a-factor, is secreted by an 
alternative mechanism [2,3]. Required for its secretion 
is the Ste6 protein, a member of the ABC (ATP Binding 
Cassette) transporter family [4,5]. The a-factor is syn- 
thesized as a larger precursor (pro-a-factor) [6]. Mature 
a-factor is generated through a series of processing 
events [7,8]. First, it is farnesylated at a cysteine residue 
close to the C-terminus, then the last three amino acids 
are removed and the cysteine is carboxymethylated at 
the newly exposed hydroxyl-group. These modifications 
are thought to be required for membrane association of 
a-factor. After proteolytic removal of the pro-sequence 
the mature farnesylated odeca-peptide is released into 
the medium. 
We were interested in finding out whether a-factor 
fused to the C-terminus of a passenger protein could 
serve as a secretion signal directing the secretion of the 
fusion protein. To analyze the localization of a-factor 
fusions we used the mouse dihydrofolate reductase 
(DHFR) as a passenger protein. Here we present results 
showing that the C-terminal modifications of a-factor 
do occur with the fusion proteins whereas secretion 
seems to be prevented, perhaps due to aggregate forma- 
tion within the cell. 
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2.1. Media and strains 
The strains were grown in minimal medium (SD) containing 0.7% 
yeast nitrogen base without amino acids (Difco), 1% casamino acids 
(Difco) and 2% glucose. The genotypes of the strains used are: 
DBY2063 MATa leu.2 ura3, K91-3b MATa cryR his4 leu2 lys2 stel6 
trpl tyrl ura.3. 
2.2. Plasmid constructions 
The plasmids encoding the DHFR-a-factor fusions were con- 
structed by inserting PCR fragments of the DHFR and MFAI genes 
into the expression plasmid, pBM272 [9], as indicated in Fig. 1. Stand- 
ard procedures were used for plasmid construction [lo]. 
2.3. Farnesylation assay 
Cells were resuspended in famesylation buffer (50 mM Tris-Cl, pH 
7.5, 50 PM zinc acetate, 20 mM KCl, 1 mM DTT) containing 1 mM 
PMSF, and lysed by agitation with glass beads. The extracts were 
diluted to a protein concentration of 5 ,&,l. 10 ~1 of extract (= 50 pg 
of protein) were mixed with 14~1 farnesylation buffer and 1~1 [‘HIfar- 
nesylpyrophosphate (Amersham, 20 pmol, 0.2 &i) and incubated at 
37°C for 1 h. After the addition of 10~1 of 4x sample buffer (4% SDS, 
250 mM Tris-Cl, pH 6.8, 40% glycerol, 0.04% bromphenolblue) the 
samples were heated to 95°C for 3 min and separated on a 15% SDS 
gel. The gel was lixed in 7% acetic acid/20% methanol, soaked in 
amplify (Amersham), dried and exposed to Kodak XGmat AR him. 
3. RESULTS 
3.1. Expression of DHFR-a-factor fusions 
To be able to decide whether the pro-sequence is 
required as a signal for the maturation or export of 
a-factor we constructed a fusion where the entire pro-a- 
factor was fused to the DHFR gene (pRK63) and an- 
other fusion where only the sequence coding for the 
mature part of a-factor, including the additional three 
C-terminal residues, was fused to DHFR (pRK47). In 
another construct, the pro-sequence of a-factor was 
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Fig. 1. Structure of the DHFR-a-factor fusions. The two pro-a-factor 
proteins encoded by the h4FAl and MFA2 genes are shown at the top 
of the diagram. Homologous regions in the pro-sequence are boxed. 
The two different a-factor variants differ in one amino acid marked 
by an asterix. Precise in-frame fusions were generated using PCR 
fragments. Suitable restriction sites were incorporated at the ends of 
the fragments to facilitate cloning. 
placed at the N-terminus of the fusion while the mature 
a-factor sequence was at the C-terminus (pRK66). 
The fusions were expressed from a centromer plasmid 
under the control of the GAL1 promoter. Cell extracts 
were prepared and analyzed by SDS-PAGE and West- 
ern blotting. The different proteins were clearly detecta- 
ble in cell extracts (Fig. 2). The mobility of the fusion 
proteins approximately corresponded to the size of the 
proteins derived from the DNA sequence (M, of 
DHFR = 21.5 kDa, M, of pro-a-factor = 3.9 kDa, M, 
of mature a-factor = 1.4 kDa). Faster migrating bands 
observed for pRK66 are probably processed forms of 
the protein. 
To assay for the presence of fusion proteins in the 
culture supernatant, proteins from 5 ml of the cell-free 
culture supernatant were TCA-precipitated, separated 
on a SDS-gel and analyzed by Western blotting with 
anti-DHFR antibodies. Using this regimen no specific 
immunoreactive bands could be detected (limit of detec- 
tion: about 10-20 ng of DHFR protein). a-Factor has 
a tendency to stick to glass surfaces, therefore we rinsed 
the culture flask with propanol[2], but we were not able 
to detect the fusion proteins in the propanol wash. 
There is the possibility that the internal a-factor is com- 
peting with the export of our recombinant fusion pro- 
teins. Therefore, we expressed a DHFR-a-factor fusion 
protein from a construct equivalent to pRK63 in the 
a-factor deletion strain, SM1229 (MATcl Amful Amfa2) 
[l I]. Even with this strain, however, we were not able 
to detect the fusion proteins in the culture supernatant. 
Therefore, we have to conclude (within the limits of 
detection) that our fusion proteins are not secreted. 
3.2. The DHFR-a-factor fusion proteins can be sedi- 
mented by centrifugation 
Cell extracts containing the DHFR-a-factor fusions 
were prepared by lysis of spheroplasts and spun at 
100,000 x g for 1 h. All three DHFR-a-factor fusion 
constructs behaved similarily in that about 90% of the 
fusion protein was found in the pellet fraction (Fig. 3). 
In contrast, the DHFR protein without the a-factor 
extension was found in the supernatant (not shown). To 
find out whether the fusion proteins are associated with 
membranes or contained within an organelle we per- 
formed a solubilization experiment. As can be seen from 
Fig. 3 the DHFR-a-factor fusion protein is not solubil- 
ized by treatment with 1 M NaCI, 0.2 M Na&O,, pH 
11, and 2% Triton X-100. Only 10 M urea was able to 
solubilize about half of the protein. As a control we used 
antibodies against the /?-subunit of the mitochondrial 
F,ATPase which is a pheripheral membrane protein. As 
expected, this protein can be solubilized in the same 
extracts by treatment with 0.2 M Na,CO, pH 11, and 
2% Triton X-100. It was also partially solubilized by 
urea treatment. From these results we conclude that the 
fusion protein is not membrane associated. The most 
likely explanation for the sedimentation of the proteins 
is aggregate formation due to the highly hydrophobic 
a-factor moiety. 
3.3. The DHFR-a-factor fusions are farnesylated 
To see whether farnesyltransferase is able to recog- 
nize the DHFR-a-factor fusions as a substrate, we ana- 
PRK 66 63 47 46 
STE16 + - + - + - + - kDa 
- 66 
- 43 
- 31 
- 14 
Fig. 2. Famesylation of DHFR-a-factor fusions. The mobility of the 
fusion proteins prepared from the wild-type strain, DBY2063(+), and 
from the stel6 strain, K91-3b (-), was compared on a 12.5% SDS-gel. 
Immunoreactive bands were detected by Western blotting using anti- 
DHFR antibodies. 
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Fig. 3. Solubilixation experiment. Extracts from DBY2063 containing the plasmid, pRK47, were incubated for 30 min at 4°C under the conditions 
indicated (lanes l-5). Then the extracts were centrifuged for 1 h at 100,000 x g. Equal portions of the supematant (S) and pellet (P) fractions were 
loaded onto a 12.5% SDS-gel (T = total extract). Immunoreactive bands were detected by Western blotting using antibodies against he B-subunit 
of F,ATPase and against DHFR. 
lyzed the fusions for the presence of C-terminal modifi- 
cations. First, we compared the gel mobility of fusions 
prepared from a wild-type strain and from a strain defi- 
cient in farnesyltransferase activity (steZ61ruml) [ 12,131. 
The proteins extracted from the de16 strain migrated 
slightly slower on SDS-gels than the proteins prepared 
from the wild-type strain (Fig. 2), an indication that 
these proteins are modified. The control protein without 
an a-factor extension (pRK46) and the fusion encoded 
by pRK63 did not show an altered mobility in the ste16 
strain. 
To demonstrate more directly that the fusions are 
farnesylated, we used an in vitro farnesylation assay. 
Cell extracts prepared from the ste16 strain expressing 
the different (unmodified) fusion proteins were mixed 
with extracts from a wild-type MATa strain furnishing 
the farnesyltransferase activity. The mixed extracts were 
incubated with [3H]farnesylpyrophosphate. The pro- 
teins were separated on a SDS-PAGE gel and analyzed 
by autoradiography (Fig. 4). Four protein bands of 
apparent sizes of 34,44,X) and 70 kDA were constantly 
detected, irrespective of the type of DHFR fusion pro- 
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Fig. 4. In vitro famesylation of the DHFR-a-factor fusion proteins. 
Extracts from the plasmid containing stel6 strain K91-3b and from 
the wild-type strain, DBY2063, were mixed and incubated with 
[‘Hlfamesylpyrophosphate. The labeled proteins were separated on a 
15% SDS-gel and analyzed by autoradiography. Lanes 1, 5 ,~l 
steld + 5 ,u1 wild-type extract; lanes 2, 1 ~1 steld + 9 ~1 wild-type 
extract. 
tein present in the extract. No farnesylated proteins 
could be detected using either of the two extracts alone 
(not shown). This indicates that farnesylation occurs 
very rapidly so that there are no proteins left in the 
wild-type extract that can be labeled with the radioac- 
tive substrate. 
The mobility of one band, however, was dependent 
on the type of fusion protein present in the extracts. This 
band could not be detected in the extracts containing the 
DHFR protein without a-factor extension. The fusion 
proteins carrying the pro-sequence of a-factor in addi- 
tion to the mature sequence (pRK63 and pRK66) gave 
rise to a slower migrating band compared to the fusion, 
which only has the mature a-factor sequence at its C- 
terminus (pRK47). From these results it is clear that all 
fusions carrying a-factor sequences at their C-termini 
are farnesylated. Thus farnesyltransferase is able to ac- 
cept the heterologous fusion proteins as a substrate. The 
pro-sequence is not required as a signal for far- 
nesyltransferase as the 15 C-terminal amino acids are 
sufficient to direct the farnesylation of the fusion pro- 
tein (pRK47). 
The pRK63 fusion protein is farnesylated, as demon- 
strated by the in vitro experiment. This protein, how- 
ever, had the same gel mobility when it was prepared 
form a de16 and from a wild-type strain. What exactly 
causes the mobility shift in the other fusions is not clear 
(but the same shift in mobility was also observed for the 
Ras2 protein). It is difficult to predict how the addition 
of a farnesyl moiety affects the mobility. The removal 
of the last three amino acids, however, should lead to 
a slightly faster migrating protein. One possible expla- 
nation is that the observed shift in mobility is mainly 
caused by the removal of the last three amino acids and 
by the loss of one negative charge due to the carbox- 
ymethylation. The results obtained with the pRK63 fu- 
sion could be explained by the assumption that only 
farnesylation occurs while further processing steps are 
prevented e.g. due to improper folding of this fusion 
protein. 
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4. DISCUSSION REFERENCES 
We have examined the potential of a-factor to serve 
as a secretion signal for heterologous proteins. Al- 
though we were able to demonstrate that the first step 
in the maturation and export pathway of a-factor, the 
farnesylation, occurs with the DHFR-a-factor fusions, 
we could not detect the proteins outside the cell. There 
are several possibilities to explain these findings: (i) the 
Ste6 translocator is not able to accomodate a polypep- 
tide larger than a-factor; (ii) the farnesylation of the 
DHFR-a-factor fusions is not sufficient for anchoring 
the protein in the membrane and therefore the probabil- 
ity of a productive interaction with the Ste6 translocator 
may be too low; (iii) the folding of the DHFR-fusions 
is not compatible with membrane translocation by Ste6. 
The translocation of the DHFR protein through the 
membrane seems to be very sensitive to alterations in 
the folding of the protein. Binding of methotrexate to 
DHFR, which presumably stabilizes the native struc- 
ture of the protein, inhibits mitochondrial import [14]. 
In line with this notion is the finding that the fusion 
proteins probably form protein aggregates in the cell. 
This is an indi~tion that the folding of the protein is 
altered. 
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